IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Acquires 30,000 Shares

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin acquired 30,000 shares of IRIDEX stock in a transaction dated Friday, January 23rd. The stock was purchased at an average price of $1.48 per share, for a total transaction of $44,400.00. Following the completion of the acquisition, the insider directly owned 1,001,299 shares in the company, valued at approximately $1,481,922.52. This represents a 3.09% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

IRIDEX Trading Up 2.2%

IRIDEX stock opened at $0.90 on Friday. The company has a fifty day simple moving average of $0.73 and a 200-day simple moving average of $0.95. The stock has a market cap of $15.78 million, a P/E ratio of -4.49 and a beta of 0.67. IRIDEX Corporation has a 12-month low of $0.61 and a 12-month high of $1.65.

IRIDEX (NASDAQ:IRIX) last posted its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The company had revenue of $12.57 million during the quarter, compared to analysts’ expectations of $13.59 million. As a group, sell-side analysts forecast that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, IRIDEX currently has a consensus rating of “Hold” and a consensus price target of $3.00.

Key IRIDEX News

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
• Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
• Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
• Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

Institutional Investors Weigh In On IRIDEX

A number of institutional investors and hedge funds have recently bought and sold shares of IRIX. Bank of New York Mellon Corp acquired a new position in IRIDEX in the second quarter valued at $29,000. Diversify Advisory Services LLC acquired a new stake in shares of IRIDEX during the second quarter worth about $30,000. Diversify Wealth Management LLC purchased a new stake in shares of IRIDEX in the 1st quarter valued at about $35,000. United Capital Financial Advisors LLC purchased a new stake in shares of IRIDEX in the 2nd quarter valued at about $41,000. Finally, Thompson Davis & CO. Inc. boosted its position in shares of IRIDEX by 66.5% in the 1st quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 18,944 shares during the period. 20.10% of the stock is owned by hedge funds and other institutional investors.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.